TCON News and Press, TRACON Pharmaceuticals Inc. From 02/18/21

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform ...

Click here to read the previous top NASDAQ pharma stocks article. 2020 wasn’t without challenges for the pharmaceutical market, which like other sectors is bound to face lasting impacts from the COVID-19 pandemic. That being said, the major underlying drivers for ...

SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

TRACON Pharmaceuticals (TCON) has entered into a securities purchase agreement with an existing investor to sell an aggregate of 520,961 common shares in a registered direct offering at $9.61 per for the aggregate gross proceeds of $5M.Closing date is December 30, 2020. Net proceeds from the ...

SAN DIEGO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform ...

TRACON Pharmaceuticals (TCON) inks securities purchase agreement with investors for the sale of 1.1M shares of common stock in a registered direct offering at $8.06/share, for expected gross proceeds of $8.8M. Net proceeds will be used to fund the ENVASARC study of envafolimab in sarcoma, fur...

SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform ...

TRACON Pharmaceuticals ([[TCON]] +2.8%) has initiated dosing in Phase 2 ENVASARC trial, evaluating envafolimab for undifferentiated pleomorphic sarcoma or myxofibrosarcoma, type of cancer in soft tissue. Interim data is expected in mid-2021.Primary objective of this 160-subject tria...